Free tool
FAERS Monitor: Danziten
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219293 or its brand name (Danziten, Nilotinib Tartrate). Reports on generic versions are filed under their own applications.
Reports
4,215
Serious
3,850
91% of reports
Hospitalization
835
Death reported
638
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug intolerance430
- drug ineffective354
- fatigue353
- drug resistance349
- diarrhoea344
- dyspnoea338
- nausea317
- headache311
- myalgia284
- arthralgia282
- abdominal pain274
- pleural effusion274
- pyrexia261
- pruritus257
- asthenia254
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 4 |
| 2008 | 12 |
| 2009 | 17 |
| 2010 | 19 |
| 2011 | 43 |
| 2012 | 95 |
| 2013 | 88 |
| 2014 | 154 |
| 2015 | 157 |
| 2016 | 215 |
| 2017 | 177 |
| 2018 | 267 |
| 2019 | 440 |
| 2020 | 375 |
| 2021 | 347 |
| 2022 | 323 |
| 2023 | 306 |
| 2024 | 365 |
| 2025 | 386 |
| 2026 | 425 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,944 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug resistanceSignal | 349 | 68.7 | 62.1 | 22,934 |
| pleural effusionSignal | 274 | 22.6 | 20.1 | 5,616 |
| drug intoleranceSignal | 430 | 22.3 | 20.4 | 8,731 |
| myalgiaSignal | 284 | 8.3 | 7.5 | 1,841 |
| abdominal painSignal | 274 | 5.9 | 5.2 | 1,117 |
| pyrexiaSignal | 261 | 3.8 | 3.3 | 536 |
| arthralgiaSignal | 282 | 3.4 | 3.0 | 481 |
| astheniaSignal | 254 | 3.4 | 3.0 | 429 |
| pruritusSignal | 257 | 3.3 | 3.0 | 426 |
| dyspnoeaSignal | 338 | 3.0 | 2.7 | 455 |
| diarrhoeaSignal | 344 | 2.7 | 2.4 | 366 |
| headacheSignal | 311 | 2.5 | 2.2 | 280 |
| fatigueSignal | 353 | 2.3 | 2.0 | 257 |
| nausea | 317 | 2.0 | 1.8 | 163 |
| drug ineffective | 354 | 1.3 | 1.2 | 32 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.